Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 10:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Ranexa Clear all
Completed Not applicable Interventional Results available

Treatment With Ranolazine in Microvascular Coronary Dysfunction (MCD): Impact on Angina Myocardial Ischemia

NCT01342029
View directory record Official record
Conditions
Microvascular Coronary Dysfunction (MCD)
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Los Angeles, California • Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Sep 15, 2026, 10:44 AM EDT
Terminated Phase 2 Interventional Results available

The Use of Ranolazine for Atrial Fibrillation and Diastolic Heart Failure

NCT01887353
View directory record Official record
Conditions
Atrial Fibrillation, Heart Failure
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Jul 19, 2015 · Synced Sep 15, 2026, 10:44 AM EDT
Completed Phase 4 Interventional Results available

Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina

NCT01425359
View directory record Official record
Conditions
Angina Pectoris, Coronary Artery Disease, Type 2 Diabetes Mellitus
Interventions
Ranolazine, Ranolazine placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
949 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
20
States / cities
Little Rock, Arkansas • Merced, California • Moreno Valley, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2014 · Synced Sep 15, 2026, 10:44 AM EDT
Completed Phase 4 Interventional Results available

Ranolazine and Microvascular Angina by PET in the Emergency Department

NCT02052011
View directory record Official record
Conditions
Microvascular Angina
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
30 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Sep 15, 2026, 10:44 AM EDT
Completed Phase 4 Interventional Results available

An Open-label, Multi-center Study Evaluating the Validity, Reliability, and Responsiveness of a New Female-specific Angina Questionnaire in Women With Chronic Angina Treated With Ranolazine Extended-release Tablets (CVT 3041)

NCT00644332
View directory record Official record
Conditions
Chronic Angina
Interventions
Ranolazine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older · Female only
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
29
States / cities
Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2012 · Synced Sep 15, 2026, 10:44 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Assess the Effect of Severe Renal Impairment on the Pharmacokinetics, as Well as Safety/Tolerability, of Ranolazine

NCT01675973
View directory record Official record
Conditions
Severe Renal Impairment
Interventions
RANEXA
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 5, 2012 · Synced Sep 15, 2026, 10:44 AM EDT
Completed Phase 2 Interventional Results available

Ranolazine Among Unrevascularized Chronic Stable Angina Patients

NCT02265796
View directory record Official record
Conditions
Angina
Interventions
Ranolazine, Sugar pill
Drug
Lead sponsor
North Florida Foundation for Research and Education
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Sep 15, 2026, 10:44 AM EDT
Terminated Phase 3 Interventional Results available

Suppression Of Atrial Fibrillation With Ranolazine After Cardiac Surgery

NCT01352416
View directory record Official record
Conditions
Heart; Dysfunction Postoperative, Cardiac Surgery
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
22 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Royal Oak, Michigan • Troy, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 5, 2017 · Synced Sep 15, 2026, 10:44 AM EDT
Completed Phase 2 Interventional Results available

Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients

NCT01648205
View directory record Official record
Conditions
Long QT Syndrome
Interventions
Placebo, Ranolazine
Drug
Lead sponsor
University of Rochester
Other
Eligibility
21 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2022 · Synced Sep 15, 2026, 10:44 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation

NCT01522651
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Ranolazine, Dronedarone, Ranolazine placebo, Dronedarone placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
15
States / cities
Beverly Hills, California • Newport Beach, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Sep 15, 2026, 10:44 AM EDT
Completed Phase 3 Interventional Results available

Effects of Ranolazine on Coronary Flow Reserve in Symptomatic Diabetic Patients and CAD

NCT01754259
View directory record Official record
Conditions
Diabetes, Type I, Diabetes, Type II, Angina, Coronary Artery Disease
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 90 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 23, 2017 · Synced Sep 15, 2026, 10:44 AM EDT
Completed Phase 2 Interventional Results available

Ranolazine Mediated PVC Reduction in Ischemic Heart Disease

NCT02360397
View directory record Official record
Conditions
Ventricular Premature Complexes, Myocardial Ischemia
Interventions
ranolazine
Drug
Lead sponsor
Kent Hospital, Rhode Island
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Warwick, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Sep 15, 2026, 10:44 AM EDT
Completed Phase 3 Interventional

Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes

NCT00099788
View directory record Official record
Conditions
Myocardial Ischemia
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
6,560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 25, 2009 · Synced Sep 15, 2026, 10:44 AM EDT
Terminated Phase 4 Interventional Results available

Study of Ranexa in Patients With Coronary Artery Disease and Painful Polyneuropathy

NCT00832572
View directory record Official record
Conditions
Coronary Artery Disease, Pain, Peripheral Nervous System Diseases, Polyneuropathy
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Houma, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 29, 2014 · Synced Sep 15, 2026, 10:44 AM EDT
Withdrawn No phase listed Observational

RANOLAZINE STUDY: Speckle Tracking Derived Myocardial Strain

NCT03257683
View directory record Official record
Conditions
Severe Coronary Artery Disease, Ischaemic Myocardial Dysfunction
Interventions
Ranolazine
Drug
Lead sponsor
Saint Thomas Health
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 9, 2018 · Synced Sep 15, 2026, 10:44 AM EDT
Completed Phase 4 Interventional Results available

Pharmacokinetics of Single-Dose Oral Ranolazine in Hemodialysis Patients

NCT01435174
View directory record Official record
Conditions
End-stage Renal Disease, Cardiovascular Disease
Interventions
Ranolazine, Pharmacokinetic Blood and Dialysate Sampling, QT Interval
Drug · Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 74 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 15, 2017 · Synced Sep 15, 2026, 10:44 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Effect of Ranolazine on Postprandial Glucagon in Subjects With Type 2 Diabetes.

NCT01843127
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Ranolazine, Placebo, Exenatide
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
3
States / cities
Chula Vista, California • Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 30, 2014 · Synced Sep 15, 2026, 10:44 AM EDT
Recruiting Phase 2 Interventional

A Study of Ranolazine in ALS

NCT06527222
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Swathy Chandrashekhar, MBBS
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
6
States / cities
San Francisco, California • Jacksonville, Florida • Fairway, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 15, 2026, 10:44 AM EDT
Completed Phase 4 Interventional Results available

Effects of Ranolazine and Exercise on Daily Physical Activity Trial

NCT01948310
View directory record Official record
Conditions
Chronic Stable Angina
Interventions
Ranolazine, Aerobic Exercise, Placebo
Drug · Behavioral
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Sep 15, 2026, 10:44 AM EDT
Completed Not applicable Interventional

Low Risk Acute Coronary Syndrome

NCT01703156
View directory record Official record
Conditions
Low Risk Acute Coronary Syndrome
Interventions
Stress Test, No Stress Test
Procedure
Lead sponsor
University of Oklahoma
Other
Eligibility
30 Years to 75 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Sep 15, 2026, 10:44 AM EDT
Completed Phase 3 Interventional Results available

Ranolazine and Pulmonary Hypertension

NCT01174173
View directory record Official record
Conditions
Angina, Pulmonary Arterial Hypertension
Interventions
Ranolazine
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 80 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 10, 2018 · Synced Sep 15, 2026, 10:44 AM EDT
Completed Phase 3 Interventional Results available

Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus

NCT01494987
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Ranolazine, Placebo, Glimepiride, Diet, Exercise
Drug · Behavioral
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
431 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
46
States / cities
Mesa, Arizona • Tucson, Arizona • Pine Bluff, Arkansas + 39 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2014 · Synced Sep 15, 2026, 10:44 AM EDT
Not listed Phase 4 Interventional

Effect of Ranolazine on Activity Level in Patients With Angina After FFR Based Deferred Intervention (REPTAR)

NCT03044964
View directory record Official record
Conditions
Angina
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Amit Malhotra, MD
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Southaven, Mississippi
Source: ClinicalTrials.gov public record
Updated Feb 6, 2017 · Synced Sep 15, 2026, 10:44 AM EDT
Completed Phase 2 Interventional Results available

Microvascular Coronary Disease In Women: Impact Of Ranolazine

NCT00570089
View directory record Official record
Conditions
Myocardial Ischemia
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 9, 2019 · Synced Sep 15, 2026, 10:44 AM EDT